Companies
MSD Animal Health
Sequivity RNA particles — Custom RNA replicon vaccines.
- Country
- Netherlands
GMP EU
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| livestock-aqua | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisemaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $5.6 billion (2023) | msd-animal-health.com |
| Capacity | 55 billion doses per year across all production, with one facility producing 150 million vaccines per day | brabantbusinessregion.com · investinholland.com · msd.nl |
| Production site | Boxmeer, Netherlands | investinholland.com · msd.nl · msd-animal-health.nl |
| Headcount | 800-900 employees at MSD Animal Health Nederland (Boxmeer site reports ~2,000 employees) | msd.nl |
| Regulatory approval | Sequivity RNA particle platform is licensed by the USDA for multiple swine applications in the US | pmc.ncbi.nlm.nih.gov · merck-animal-health-usa.com · msd-animal-health.com |
Independent sources: brabantbusinessregion.com · investinholland.com · merck-animal-health-usa.com · msd.nl · pmc.ncbi.nlm.nih.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Veterinary biotech & mRNA veterinary drugs | livestock-aqua | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.